



US007491504B2

(12) **United States Patent**
Shan et al.

(10) **Patent No.:** **US 7,491,504 B2**
(45) **Date of Patent:** **Feb. 17, 2009**

(54) **METHOD FOR DETECTING OVARIAN CANCER**

(75) Inventors: **Lian Shan**, Broadview Heights, OH (US); **Stanley L. Hazen**, Gates Mills, OH (US)

(73) Assignees: **Frantz Biomarkers, LLC**, Mentor, OH (US); **The Cleveland Clinic Foundation**, Cleveland, OH (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **11/595,634**

(22) Filed: **Nov. 10, 2006**

(65) **Prior Publication Data**

US 2007/0196875 A1 Aug. 23, 2007

Related U.S. Application Data

(60) Provisional application No. 60/738,849, filed on Nov. 22, 2005.

(51) **Int. Cl.**
G01N 33/574 (2006.01)

(52) **U.S. Cl.** **435/7.25**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,776,753	A	7/1998	Hillman et al.	
6,500,633	B1	12/2002	Compton et al.	
6,830,932	B1 *	12/2004	Danne et al.	436/86
2002/0123084	A1 *	9/2002	Mills et al.	435/7.23
2002/0150955	A1	10/2002	Mills et al.	
2004/0137541	A1	7/2004	Mills et al.	
2004/0143461	A1	7/2004	Watkins	

OTHER PUBLICATIONS

Merchant, T.E., Kasimos, J.N., De Graaf, P.W., Minsky, B.D., Gierke, L.W., and Glonek, T. Phospholipid profiles of human colon cancer using 31P magnetic resonance spectroscopy. *International Journal of Colorectal Disease*, 1991. vol. 6, pp. 121-126.*

Borsche, T. Plasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic values. *Archives of Gerontology and Geriatrics*, 2001. vol. 32, pp. 283-294.*

U.S. Appl. No. 11/601,076, filed Nov. 17, 2006, Confirmation No. 6866.

Stevens et al., "Class F Thy-1-negative Murine Lymphoma Cells Are Deficient in Ether Lipid Biosynthesis," *J. Biol. Chem.*, Sep. 1990, vol. 265, No. 26, pp. 15653-15658.

Zoeller et al., "Isolation of Animal Cell Mutants Deficient in Plasmalogen Biosynthesis and Peroxisome Assembly," *Proc. Natl. Acad. Sci. of U.S.A.*, Jul. 1986, vol. 83, pp. 5170-5174.

Hale et al., "The selective activation of the cardiac sarcolemmal sodium-calcium exchanger by plasmalogenic phosphatidic acid produced by phospholipase D," *FEBS Letters*, Jan. 1998, 422 (2), pp. 247-251.

Petricoin et al., Use of proteomic patterns in serum to identify ovarian cancer, *The Lancet*, Feb. 2002, 359 (9306), pp. 572-577.

Zhu et al., "Detection of cancer-specific markers amid massive mass spectral data," *PNAS USA*, Dec. 2003, 100 (25), pp. 14666-14670.

Zhen Zhang et al., "Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer," *Cancer Research*, 64, 5882-5890, Aug. 15, 2004.

Han et al., "Diabetes-induced changes in specific lipid species in rat myocardium," *The Biochemical Journal*, (2000), vol. 352 (Pt) : 79-89.

Dueck et al., "The modulation of choline phosphoglyceride metabolism in human colon cancer," *Molecular and Cellular Biochemistry*, (1996), vol. 162 (2) : 97-103.

Morita et al., "Phospholipid turnover in the inflamed intestinal mucosa: Arachidonic acid-rich phosphatidyl/plasmenylethanolamine in the mucosa in inflammatory bowel disease," *Journal of Gastroenterology*, (1999), vol. 34 (1) : 46-53.

Zhu et al., "Molecular species composition of glycerophospholipids in rat sciatic nerve and its alteration in streptozotocin-induced diabetes," *Biochimica et Biophysica Acta.*, (1993), vol. 1168 (1) : 1-12.

Yavin et al., "Docosahexaenoic Acid Abundance in the Brain: A Biodevice to Combat Oxidative Stress," *Nutr. Neuroscience*, (2002), vol. 5 (3), 149-157.

Rapport and Alonzo, "Identification of Phosphatidyl Choline as the Major Constituent of Beef Heart Lecithin," *J. Biol. Chem.*, (1955), 217 : 199-204.

Morikawa et al., "A Simple and Sensitive Determination for Plasmalogen Lysophosphatidylethanolamine in Rabbit Platelets," *Thrombosis Research*, (1989), 55: 427-438.

Shaikh, "Assessment of Various Techniques for the Quantitative Extraction of Lysophospholipids from Myocardial Tissues," *Analytical Biochemistry*, (1994), 216:313-321.

Engelmann et al., "Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins," *Biochem. Biophys. Res. Commun.*, (1994), vol. 204, No. 3, 1235-1242.

(Continued)

Primary Examiner—Misook Yu

Assistant Examiner—Mark Halvorson

(74) Attorney, Agent, or Firm—Frishauf, Holtz, Goodman & Chick, P.C.

(57) **ABSTRACT**

A method of detecting ovarian cancer in a female test subject comprising determining the amount of plasmenyl-PA or a biomarker having a mass charge ratio of approximately 655.3 in a sample of a bodily fluid taken from the female test subject and comparing the amount of plasmenyl-PA (or the biomarker) in the sample of the bodily fluid taken from the female test subject to a range of amounts of plasmenyl-PA (or the biomarker) found in samples of bodily fluids taken from a group of normal female subjects of the same species as the female test subject and lacking ovarian cancer, whereby a lower amount of the plasmenyl-PA (or the biomarker) in the sample of the bodily fluid taken from the female test subject indicates the presence of ovarian cancer.